Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525

Aurinia Pharmaceuticals Inc.

2022-FY EPS reported -$0.76 revenue$134,030,000

Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.
Net product revenue Q4 ~$28.3M, full-year ~$103.5M; 2022 guidance achieved.
LUPKYNIS patients on therapy at Dec 31, 2022: 1,525, up from 1,354 at Sep 30, 2022.
Q4 patient start forms ~406, compared to 374 in Q3 2022.
Reiterates 2023 net product revenue guidance of $120-140M; cash & investments ~$388.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2022 results: revenue approximately $28.4 million and $134.0 million. Guidance reaffirmed.

Period: fourth quarter and full-year 2022
Revenue: approximately $28.4 million and $134.0 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-000762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.